Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study

Fig. 2

Kaplan-Meier analysis of time to treatment discontinuation and overall survival. Kaplan-Meier analysis of time to treatment discontinuation (a) and overall survival (b) among patients who received cetuximab as salvage therapy for advanced KRAS wild type (exon 2 non-mutant) CRC. Patients were divided according to primary tumor site (left side: splenic flexture to rectum; right side: cecum to hepatic flexture). The P values were conducted using the log-rank test

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us